drug · antibody
ELREXFIO
updated 5mo agoby $PFE PFIZER INC🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 6Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for multiple myeloma and neoplasm and 2 investigational indications.
targets
T cell surface glycoprotein CD3Tumor necrosis factor receptor superfamily member 17
all catalysts(0)
nothing on the calendar yet
Trials studying ELREXFIO
- phase1A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
- phase1A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
- phase2Elranatamab in R/R Multiple Myeloma
- phase3MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- phase2AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- phase1A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
- phase2A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
- phase3Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
News(8)
- GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750MAfter inking a T cell engager pact with Chimagen Biosciences a few years ago, GSK is back for more, this time acquiring a multiple myeloma program from the antibody specialist.biospace · 19d ago
- GSK doubles down on Chimagen with $750M multiple myeloma wagerGSK has bet up to $750 million on a Chimagen Biosciences trispecific T-cell engager, positioning the Big Pharma to start phase 1 development of the multiple myeloma drug candidate next year. The de…fiercebiotech · 20d ago
- Trailing rivals, AbbVie scores win with dual-acting myeloma drugThe drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.biopharma_dive · 1mo ago
- AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trialAbbVie released positive phase 3 data Thursday showing that its bispecific T-cell engager etentamig improved response rates and progression-free survival in patients with relapsed/refractory multip…fiercebiotech · 1mo ago
- Regeneron ends eye disease trial for anti-CD3 antibody following safety reviewRegeneron has hit the brakes on the phase 1/2a trial for an experimental eye inflammation treatment, following an adverse event that tilted the drug’s risk/benefit profile in the wrong direction.fiercebiotech · 1mo ago
- CellCentric raises $220M for a ‘transformative’ multiple myeloma medicineA Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech sees as a differentiated option for patients with persistent disease.biopharma_dive · 5mo ago
- Pfizer earns positive Phase 3 in multiple myeloma; ICON overstated revenuePfizer’s positive Phase 3 data in multiple myeloma: The company’s Elrexfio produced a “statistically significant and clinically meaningful improvement” in progression-free survival in patients with…endpoints · 5mo ago
- FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotechThrough two pioneering studies, Amgen and AstraZeneca will share study data with FDA scientists as it’s accrued. Elsewhere, Lilly inked a gene editing deal and Pfizer reported success for a multipl…biopharma_dive · 5mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that